When it comes to winning intellectual property trials, few law firms rival Heller Ehrman's IP Litigation Practice Group. In San Diego, the firm has 25 top IP litigators, including senior litigators David Kleinfeld, John Benassi and Alan Blankenheimer, who represent Fortune 500 clients as well as earlier stage technology companies.
Leaders of San Diego's technology sector believe they have a lot to offer the high-tech workers of the United States. The trouble, they say, is the United States doesn't have many such workers to offer them.
Seattle, San Francisco, Boston and San Diego are widely recognized and established biotech clusters. Who will be next? Phoenix, Salt Lake City, Chicago, Madison, Albuquerque, Orlando or Atlanta?
FFF Enterprises has become a leading provider of human plasma products, vaccines and clinical trial drugs by offering a secure distribution network, responding to the marketplace and keeping its customers happy.
All markets are cyclical and the signs are that the world's semiconductor market is poised for an upturn. And that is great news for San Diego based Cymer (Nasdaq: CYMI) -- the world's leading manufacturer of excimer lasers.
Your company has invested valuable time and resources in developing new biotechnology - now it's time to think about whether you should license out all or part of your rights in your new inventions. Why would you license your intellectual property rights to another party?
Connect, a technology and business accelerator dedicated to the success and growth of San Diego-based technology and life science companies, continues to nurture the local pipeline of innovation and commercialization through a range of new and enhanced programs -- many of them free to the public thanks to the generous support of Connect's members.
Connect, a technology and business accelerator dedicated to the success and growth of San Diego-based technology and life science companies, announced the launch of the Venture Roundtable.
Optimer Pharmaceuticals is a hard company to find. Nestled in an executive park hidden beside Interstate 5 in Sorrento Valley, the office lacks the large signage and perfectly manicured landscaping that surrounds some of the other nearby buildings.
In 1988, Biosite (Nasdaq: BSTE) co-founders Kim Blickenstaff, Kenneth Buechler, Gunars Valkirs and Richard Anderson took a gamble that paid-off. They left secure corporate jobs at Eli Lilly-owned Hybritech to develop a new method of detecting illegal drugs -- fast -- when patients presented at the emergency room.
The new drug development process is lengthy, costly and uncertain. Bringing a new drug from discovery to market may cost $800 million and take years of testing. Preclinical laboratory alone may take more than 10 years prior to submission of an Investigational New Drug (IND) application and commencement of the first human trials.
Getting a new drug to market may cost as much as $800 million. With this type of investment, patents are necessary to protect market exclusivity. A strategic, creative and effective approach to patenting pharmaceuticals is crucial to minimizing competition and maximizing profit margin.
NEW YORK -- The Bluetooth wireless standard used in cell phones and other small devices will take a leap in transmission speed, broadening its scope to enable high-definition video and files for digital music players like the iPod.
Learn about key people, innovations and trends in San Diego’s thriving tech and biotech industries.
Find out Who's Who in Tech & Biotech as we profile a few executives turning local companies into regional success stories.
Meet some of the executives behind some of San Diego's thriving technology and biotech companies, along with news about IP issues, the latest products and innovations.
Take a closer look at some of the leading CEOs turning local tech and biotech companies into regional success stories.